前收市價 | 30.86 |
開市 | 30.78 |
買盤 | 30.81 x 1500 |
賣出價 | 30.93 x 100 |
今日波幅 | 30.37 - 31.22 |
52 週波幅 | 12.75 - 44.32 |
成交量 | |
平均成交量 | 1,806,644 |
市值 | 5.703B |
Beta 值 (5 年,每月) | 1.05 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -3.95 |
業績公佈日 | 2024年5月02日 - 2024年5月06日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 49.00 |
Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.
Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. But BridgeBio stock tumbled Monday.
BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday. The experimental drug, acoramidis, is being developed as an oral treatment for transthyretin amyloid cardiomyopathy, in which abnormal deposits of a protein called amyloid build up in the heart and can cause the organ to fail. The U.S. drugmaker will also receive tiered royalties beginning in the low-thirties percent on sales of acoramidis in Europe.